H.R.2026: Pharmaceutical Information Exchange Act

Author's Summary:  This bill amends the Federal Food, Drug, and Cosmetic Act to allow information about a new investigational medication or the investigational use of a medication approved by the Food and Drug Administration to be provided to health care entities if the information is based on reliable scientific evidence.

IB Summary:  According to Stephen Barlas: "the Pharmaceutical Information Exchange Act would allow those companies to provide information to formulary committees on investigational drugs. In the latter case, the idea is to provide health care economic information (HCEI) to insurers and their P&T committees in advance of a drug’s approval, so that insurers won’t find themselves unprepared when the Food and Drug Administration (FDA) approves expensive new drugs that blow up insurance company pharmacy budgets. Broader HCEI would ostensibly make insurers better prepared to consider value-based formulary contracts." read more here - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614408/

Status:   Introduced in the House on 01/17/2018.  Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14.

Links: https://www.congress.gov/bill/115th-congress/house-bill/2026?r=1